Literature DB >> 29661781

Relation of Aortic Stiffness to Left Ventricular Remodeling in Younger Adults With Type 2 Diabetes.

Gaurav S Gulsin1, Daniel J Swarbrick1, William H Hunt1, Eylem Levelt1, Matthew P M Graham-Brown2, Kelly S Parke1, Joanne V Wormleighton1, Florence Y Lai1, Thomas Yates2, Emma G Wilmot3, David R Webb4, Melanie J Davies4, Gerry P McCann5.   

Abstract

Individuals with type 2 diabetes have a three- to fivefold increased risk of developing heart failure. Diabetic cardiomyopathy is typified by left ventricular (LV) concentric remodeling, which is a recognized predictor of adverse cardiovascular events. Although the mechanisms underlying LV remodeling in type 2 diabetes are unclear, progressive aortic stiffening may be a key determinant. The aim of this study was to assess the relationship between aortic stiffness and LV geometry in younger adults with type 2 diabetes, using multiparametric cardiovascular MRI. We prospectively recruited 80 adults (aged 18-65 years) with type 2 diabetes and no cardiovascular disease and 20 age- and sex-matched healthy control subjects. All subjects underwent comprehensive bio-anthropometric assessment and cardiac MRI, including measurement of aortic stiffness by aortic distensibility (AD). Type 2 diabetes was associated with increased LV mass, concentric LV remodeling, and lower AD compared with control subjects. On multivariable linear regression, AD was independently associated with concentric LV remodeling in type 2 diabetes. Aortic stiffness may therefore be a potential therapeutic target to prevent the development of heart failure in type 2 diabetes.
© 2018 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2018        PMID: 29661781     DOI: 10.2337/db18-0112

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  14 in total

Review 1.  Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.

Authors:  Ralph A DeFronzo; W Brian Reeves; Alaa S Awad
Journal:  Nat Rev Nephrol       Date:  2021-02-05       Impact factor: 28.314

Review 2.  Basic Mechanisms of Diabetic Heart Disease.

Authors:  Rebecca H Ritchie; E Dale Abel
Journal:  Circ Res       Date:  2020-05-21       Impact factor: 17.367

Review 3.  The Diabetic Cardiorenal Nexus.

Authors:  John A D'Elia; George P Bayliss; Larry A Weinrauch
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

Review 4.  Diabetic cardiomyopathy: prevalence, determinants and potential treatments.

Authors:  Gaurav S Gulsin; Lavanya Athithan; Gerry P McCann
Journal:  Ther Adv Endocrinol Metab       Date:  2019-03-27       Impact factor: 3.565

5.  Phenotyping diabetic cardiomyopathy in Europeans and South Asians.

Authors:  Elisabeth H M Paiman; Huub J van Eyk; Maurice B Bizino; Ilona A Dekkers; Paul de Heer; Johannes W A Smit; Ingrid M Jazet; Hildo J Lamb
Journal:  Cardiovasc Diabetol       Date:  2019-10-11       Impact factor: 9.951

6.  The impact of visceral and general obesity on vascular and left ventricular function and geometry: a cross-sectional magnetic resonance imaging study of the UK Biobank.

Authors:  Max J P van Hout; Ilona A Dekkers; Jos J M Westenberg; Martin J Schalij; Arthur J H A Scholte; Hildo J Lamb
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2020-03-01       Impact factor: 6.875

7.  Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes.

Authors:  Sharmaine Thirunavukarasu; Nicholas Jex; Amrit Chowdhary; Imtiaz Ul Hassan; Sam Straw; Thomas P Craven; Miroslawa Gorecka; David Broadbent; Peter Swoboda; Klaus K Witte; Richard M Cubbon; Hui Xue; Peter Kellman; John P Greenwood; Sven Plein; Eylem Levelt
Journal:  Diabetes       Date:  2021-10-05       Impact factor: 9.461

8.  Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double-Blind, Randomized, Placebo-Controlled Trial.

Authors:  Elisabeth H M Paiman; Huub J van Eyk; Minke M A van Aalst; Maurice B Bizino; Rob J van der Geest; Jos J M Westenberg; Petronella H Geelhoed-Duijvestijn; Aan V Kharagjitsingh; Patrick C N Rensen; Johannes W A Smit; Ingrid M Jazet; Hildo J Lamb
Journal:  J Magn Reson Imaging       Date:  2019-12-04       Impact factor: 4.813

9.  Clinical associations with stage B heart failure in adults with type 2 diabetes.

Authors:  Gaurav S Gulsin; Emer Brady; Anna-Marie Marsh; Gareth Squire; Zin Z Htike; Emma G Wilmot; John D Biglands; Peter Kellman; Hui Xue; David R Webb; Kamlesh Khunti; Tom Yates; Melanie J Davies; Gerry P McCann
Journal:  Ther Adv Endocrinol Metab       Date:  2021-07-17       Impact factor: 3.565

10.  Rationale and design of the randomised controlled cross-over trial: Cardiovascular effects of empaglifozin in diabetes mellitus.

Authors:  Sharmaine Thirunavukarasu; Louise Ae Brown; Amrit Chowdhary; Nicholas Jex; Peter Swoboda; John P Greenwood; Sven Plein; Eylem Levelt
Journal:  Diab Vasc Dis Res       Date:  2021 May-Jun       Impact factor: 3.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.